<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430762</article-id><article-id pub-id-type="pmcid-ver">PMC12430762.1</article-id><article-id pub-id-type="pmcaid">12430762</article-id><article-id pub-id-type="pmcaiid">12430762</article-id><article-id pub-id-type="pmid">40474835</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002684</article-id><article-id pub-id-type="publisher-id">IJS-D-25-02434</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Letter to the editor: a commentary on &#8220;Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.&#8221;</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xi</given-names></name><degrees>MD</degrees><email>chenximyzxyy@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="X">Xintao</given-names></name><degrees>MM</degrees><email>zengxintao@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="P">Pei</given-names></name><degrees>MD</degrees><email>305827337@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="D">Decai</given-names></name><degrees>MD</degrees><email>decaiwang-2020@163.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jianjun</given-names></name><degrees>MD</degrees><email>wangjianjunmch@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Hepatobiliary Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China</aff><aff id="aff2"><label>b</label>Department of Urology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Department of Urology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China. Tel.: +86 17364033760 E-mail: <email>decaiwang-2020@163.com</email> (D. Wang); Department of Hepatobiliary Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, China. Tel.: +86 13698128650. E-mail: <email>wangjianjunmch@163.com</email> (J. Wang).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6520</fpage><lpage>6521</lpage><history><date date-type="received"><day>19</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6520.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6520.pdf"/><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<italic toggle="yes">Dear Editor,</italic>
</p><p>The systematic review and meta-analysis by Lu <italic toggle="yes">et al</italic><sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> provides a comprehensive assessment of the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with systemic therapy in advanced hepatocellular carcinoma (HCC). The study offers significant insights into the potential benefits of HAIC, highlighting its ability to enhance tumor control via locoregional chemotherapy delivery and induce immunogenic cell death, which amplifies the immune response to systemic therapies. This ultimately improves overall survival, progression-free survival, objective response rate, and disease control rate. Trial sequential analysis and correlation between objective response rate and overall survival further strengthen the robustness of these findings. However, several aspects warrant further discussion and refinement.</p><p>First, heterogeneity of treatment regimens is a major concern. The included studies exhibited substantial variability in the treatment regimens, with differences in HAIC agents (e.g. oxaliplatin vs. cisplatin), tyrosine kinase inhibitors (TKIs, e.g. lenvatinib, sorafenib), and immune checkpoint inhibitors (ICIs, e.g. camrelizumab, tislelizumab, sintilimab). These agents have distinct pharmacological mechanisms, immune modulation effects, and clinical efficacies<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. For instance, oxaliplatin can induce immunogenic cell death, potentially enhancing synergy with PD-1/PD-L1 inhibitors, while cisplatin primarily relies on DNA damage with less immune activation. Moreover, combinations of different TKIs and ICIs can exert varying degrees of modulation on the tumor microenvironment<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>. Despite subgroup analyses, the substantial heterogeneity in treatment regimens may obscure effect estimates and affect the interpretability of pooled outcomes. We suggest that future studies consider using network meta-analysis to directly and indirectly compare the efficacy of various combinations, while improving the reporting of treatment regimens for clearer evidence regarding individualized treatment strategies.</p><p>Second, the lack of individual patient-level data is a limitation of the current analysis. Although subgroup explorations were conducted, it remains challenging to determine whether specific subgroups &#8211; such as those with Child-Pugh B liver function or extrahepatic metastases &#8211; truly benefit from HAIC-combined therapy<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup>. We recommend that future studies incorporate individual patient data-based meta-analyses to allow for more refined stratification and better assessment of treatment effects.</p><p>Lastly, the limited geographic and population representation in the included studies is a concern. Most studies were conducted in China and other East Asian countries, where HBV-related HCC predominates, and HAIC is more commonly practiced<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>. However, in Western countries, HCC is more frequently associated with non-viral causes, such as non-alcoholic steatohepatitis and metabolic syndrome<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>. These patients often have different immune microenvironment characteristics and higher comorbidity burdens, which may affect their response to combined therapies. We recommend that future studies expand their geographic scope by incorporating multicenter prospective research to include diverse ethnicities and etiologies. Conducting etiology-based subgroup analyses will help validate the broader applicability of HAIC-combined treatment strategies.</p><p>Finally, while the study provides evidence supporting the use of HAIC combined with systemic therapy in advanced HCC, we believe that future research should focus on standardizing treatment protocols, addressing population diversity, and exploring the mechanisms underlying therapeutic responses. Further studies should also consider validating these findings in real-world settings. We look forward to high-quality, multicenter trials that incorporate elements of precision medicine to optimize comprehensive treatment strategies for advanced HCC<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup>.</p></body><back><fn-group><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 05 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>This correspondence did not require ethical approval.</p></sec><sec><title>Consent</title><p>Not applicable.</p></sec><sec><title>Sources of funding</title><p>This work did not receive any funding related to its research, authorship, or publication.</p></sec><sec><title>Author contributions</title><p>X.C., X.Z., and P.Y. found the question and wrote the draft. D.W., and J.W. revised the manuscript. X.C., X.Z., and P.Y. contributed equally to this work and shared the first authorship. D.W., and J.W. contributed equally to this work and share corresponding authorship. All authors have approved the letter.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare that they have no competing interests related to this work.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Guarantor</title><p>Jianjun Wang.</p></sec><sec><title>Provenance and peer review</title><p>This paper was not invited.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>All data analyzed or generated during this study are included in the article.</p></sec><sec><title>Declaration and use of AI</title><p>No artificial intelligence tools were used in the design, execution, or writing of this study, and our article is compliant with the TITAN Guidelines 2025.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis</article-title>. <source>Int J Surg</source><year>2025</year>;<volume>111</volume>:<fpage>3494</fpage>-<lpage>507</lpage>.<pub-id pub-id-type="pmid">40143751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000002326</pub-id><pub-id pub-id-type="pmcid">PMC12165593</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis</article-title>. <source>Front Immunol</source><year>2024</year>;<volume>15</volume>:<fpage>1430196</fpage>.<pub-id pub-id-type="pmid">39355238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1430196</pub-id><pub-id pub-id-type="pmcid">PMC11442238</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name></person-group>. <article-title>Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials</article-title>. <source>Front Pharmacol</source><year>2025</year>;<volume>16</volume>:<fpage>1535444</fpage>.<pub-id pub-id-type="pmid">40196369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2025.1535444</pub-id><pub-id pub-id-type="pmcid">PMC11973308</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial</article-title>. <source>Nat Commun</source><year>2024</year>;<volume>15</volume>:<fpage>8857</fpage>.<pub-id pub-id-type="pmid">39402023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-52700-z</pub-id><pub-id pub-id-type="pmcid">PMC11473759</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion</article-title>. <source>World J Surg Oncol</source><year>2024</year>;<volume>22</volume>:<fpage>122</fpage>.<pub-id pub-id-type="pmid">38711095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-024-03396-4</pub-id><pub-id pub-id-type="pmcid">PMC11071192</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Global, regional, and national temporal trends in incidence and mortality for liver cancer due to hepatitis B, 1990-2021: a decomposition and age-period-cohort analysis for the global burden of disease study 2021</article-title>. <source>Hepatol Int</source><year>2025</year>;<volume>19</volume>:<fpage>368</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">39702656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-024-10765-4</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of artificial INtelligence &#8211; the TITAN guideline</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>